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Abstract
Background: The Northern Territory of Australia has a very high incidence of treated end-stage kidney disease
(ESKD), largely confined to Indigenous Australians living in remote, under-resourced areas. Surveillance of chronic
kidney disease (CKD) is still in its infancy in Australia. We estimate the prevalence and rate of progression of
measured CKD across a region using inexpensive readily available laboratory information.
Methods: Using a retrospective de-identified extraction of all records with a serum creatinine or urinary albumin-
to-creatinine ratio from the single largest ambulatory pathology provider to the Top End of the Northern Territory
of Australia between 1st February 2002 and 31st December 2011, the yearly total and age-specific prevalence of
measured microalbuminuria, overt albuminuria and estimated glomerular filtration rate (eGFR) <60 ml/min/1.73 m2,
and the prevalence of progressive CKD, were calculated.
Results: There was a steady increase in the proportion tested across all health districts in the region, more
prominent in non-urban districts. In 2009, the regional adult prevalence of measured microalbuminuria and overt
albuminuria was as high as 8.1 %, overt albuminuria alone up to 3.0 % and eGFR < 60 up to 2.3 %. Rates of
progressive disease were extremely high, particularly for those with albuminuria (53.1–100 % for those with urinary
albumin-creatinine ratio > 300 mg/mmol).
Conclusions: The rates of testing, particularly in districts of high measured prevalence of markers of CKD, are
encouraging. However, extremely high rates of progressive CKD are troubling. Further describing the outcomes of
CKD in this population would require analysis of linked datasets.
Keywords: Chronic kidney disease, Estimated glomerular filtration rate, Creatinine, Urinary albumin-creatinine ratio,
Public health surveillance
Background
The Top End of the Northern Territory (NT) of
Australia is a large geographical area of over 500,000
square kilometres with a relatively small population
comprised of a largely urban centralised non-Indigenous
population and a smaller, largely remote, de-centralised
and disadvantaged Indigenous population (Fig. 1) that is
under-enumerated and culturally and linguistically
heterogeneous [1]. The poor health status of its Indigen-
ous population with high rates of chronic kidney disease
(CKD) is a public health concern in the NT [2]. There is
a single tertiary referral centre staffed by nephrologists
in Darwin.
The incidence of treated end-stage kidney disease
(ESKD) in the NT is 3–4 times national Australian
figures, and is largely confined to the Indigenous com-
munity that comprises a third of the NT’s population
[3]. At least one individual community has a reported
ESKD incidence up to 25 times the national rate [4],
amongst the highest in the world. Reports from cross-
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sectional surveys of a few individual Top End Indigenous
communities have shown a very high prevalence of albu-
minuria [5–8]. However, it is not clear if this means that
the high incidence of treated ESKD is a result of a large
burden of earlier stages of CKD, a rapid rate of progres-
sion or a higher survival rate of those with CKD to end-
stage.
The recent validation of the CKD-EPI equation for In-
digenous Australians [9], the publication of position pa-
pers regarding the use of the CKD-EPI formula for all
Australians [10] and the classification and risk stratifica-
tion of CKD [11] support a population-based approach
to determining CKD prevalence.
A few studies have examined clinical laboratory re-
sults to determine the prevalence of measured CKD
across regions [12, 13], including one in the Australian
state of Tasmania [14]. While this method cannot take
the place of a population-based random sample, it can
be an important adjunct if the population is hard to
reach due to remoteness, health service limitations or
cross-cultural and linguistic challenges. It can be par-
ticularly useful in areas where there is heightened
awareness of CKD and strategies to detect and
manage it that lead to a substantial proportion of the
population at risk to be tested as part of routine clin-
ical care. All of these circumstances apply in the Top
End of the NT [2]. For the time of this study the
Top End region of the NT was served by one domin-
ant provider of ambulatory pathology services,
Western Diagnostic Pathology (WDP, Myaree,
Western Australia, a private laboratory providing
pathology services across the NT and WA); almost all
services for dialysis and transplant patients were pro-
vided through an alternative, NT Department of
Health hospitals pathology. This allowed calculation
of the prevalence of measured CKD that largely ex-
cluded those with treated ESKD without the need for
data linkage, which has particular ethical and tech-
nical challenges for Indigenous Australians [15] and is
time consuming, expensive and still in a capacity-
building phase in Australia.
The aim of this study was to examine CKD preva-
lence and rate of progression over a 10 year period in
a geographical area with a high incidence and preva-
lence of treated ESKD using inexpensive readily avail-
able information.
Fig. 1 Map of Top End Northern Territory, with 2006 estimated resident population (ERP) by health district including proportion of adult
population Indigenous
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Methods
Study design and population
A retrospective cohort study was performed using de-
identified pathology records with NT postcodes from
1st February 2002 to 31st December 2011 from a sin-
gle pathology provider. The population included all
those with records of a serum creatinine or urinary
albumin-to-creatinine ratio (UACR) analysed by WDP.
All records were identifiable only by a laboratory
unique identifier for each individual: linkage of re-
cords to an individual was performed for clinical
purposes at the laboratory level and no other linkage
was performed. Records were matched to health
districts within the Top End region using the indi-
vidual’s postcode recorded at the time of testing and
2006 postal area concordance files available from the
Australian Bureau of Statistics (ABS) [16] and the
NT Health Department’s Health Gains Planning
Branch (HGP) [17].
Laboratory measures
All serum samples were collected into Becton Dickinson
serum separator tubes (BD SST II, Becton Dickinson,
North Ryde, NSW, Australia). Serum and urine creatin-
ine were measured using the Siemens ADVIA 2400 Jaffe
creatinine assay (Siemens Ltd. Australia and New
Zealand—Diagnostics Division, Tarrytown, N.Y, USA),
an alkaline picrate kinetic method with blank correction.
Creatinine was standardised to isotope dilution mass
spectrometry (IDMS) standards on 1st February 2002.
Percentage coefficients of variation (CVs) within run for
quality control material over an indicative 12 month
period were: Level 1 (serum creatinine 74.5 umol/L)
1.57–2.1 % CV, Level 2 (serum creatinine 523.9 umol/L)
1.32–6.91 % CV. Urine albumin was measuredusing the
Advia Chemistry 2400 method, and percentage CVs
between runs were: Level 1 (urine albumin 13.22 mg/L)
5.7 % CV, Level 2 (urine albumin 63.27 mg/L) 2.54 %
CV. UACR was reported in mg/mmol.
Outcome measures
The estimated glomerular filtration rate (eGFR) was cal-
culated using the CKD-EPI equation, as recommended
and validated for both Indigenous and non-Indigenous
Australians [9, 10]. Mean eGFR was calculated for each
year with available data, similar to previous work [14];
mean UACR was calculated similarly. Individuals were
then grouped based on their mean eGFR and UACR
levels into strata chosen to enable comparison with pre-
vious literature. Gender-specific cut-offs were used to
define microalbuminuria: for men ≥ 2.5 mg/mmol, for
women ≥ 3.5 mg/mmol.
Statistical analysis
Those with results in years before and after the year of
interest, but not in the year of interest, could reasonably
be assumed to be still alive in the Top End and were eli-
gible to be counted towards the prevalence numerator
for that year. Their result for the year of interest was as-
sumed to be the same as their previous measured result
until a new value supplanted it. For example, a person
with a mean eGFR in 2002, but no further results until
2005, was assumed to be alive in the Top End and have
the same eGFR in 2003 & 2004 until the new mean re-
sult in 2005; their 2002 mean eGFR counted for the first
3 years to the numerator of the relevant eGFR category.
Population figures for the region were used for the
prevalence denominator, taken from yearly ABS Esti-
mated Resident Population (ERP) figures [18] and
mapped to NT health districts using HGP population
concordance files [17]. All prevalence was expressed
in percentages. The total adult population (15 years
or greater) was taken as the denominator to account
in part for confounding by indication, in that those
having tests performed presumably had a clinical indi-
cation for them (and were therefore more likely to
have disease than those not tested). In addition, using
the total population as the denominator ensured that
the prevalence expressed would be more reliable as a
minimum estimate. Since all available results from the
whole population were used and the population was
not assumed to be a random sample, confidence in-
tervals were not calculated.
To examine disease progression, only data from those
with two or more serum creatinine measurements at
least 2 years apart was used. Progressive CKD was de-
fined as an average annual decline in eGFR during
follow-up of ≥2.5 ml/min/1.73 m2 per year and a last
eGFR value < 45 ml/min/1.73 m2, independent of base-
line eGFR level [11]. Average annual decline in eGFR
was calculated as last available eGFR minus baseline
eGFR divided by follow-up time (in years, minimum
two) between the two observations [11]. The prevalence
of progressive CKD was expressed as a percentage of the
tested population.
Ethical approval was given by the combined Human
Research Ethics Committee of the Northern Territory
Department of Health and Menzies School of Health Re-
search (HREC-2011-1566).
Results
Those with interstate or overseas postcodes were ex-
cluded (15,307 tests), as were those aged <15 years
(13,340 tests about 9605 individuals), as the CKD-EPI
formula performs poorly in children and adolescents
[19]. Those with serum creatinine <25 micromol/L were
also excluded as in other studies (249 tests about 146
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individuals) [13, 14]. Another 8017 tests about 1829 in-
dividuals did not match to a valid postcode, and were
excluded. The remaining 495,672 tests about 127,526 in-
dividuals were included for analysis.
Population characteristics are outlined in Table 1.
Over most of the period, there was an increase in the
number of people being tested with either a serum cre-
atinine or UACR; this was consistently weighted towards
the major population centre, the Darwin Urban district.
However, the proportion of the regional population
tested was highest in the Darwin Rural district and low-
est in the East Arnhem district over the period (Fig. 2).
In each region, there was a rise in proportion tested with
increasing age for age groups up to 74 years. In every
age group 4–6 % more women than men were tested. In
any year, most people tested had only one test. For ex-
ample, in 2009, 95.2 % of those with a serum creatinine
and 99.9 % of those with a UACR had only one test.
A sharp rise in absolute numbers tested (Table 1) and
in the proportion of the total population tested was
noted from 2002 to 2004, with subsequent smaller yearly
rises to 2008–9 and then a plateau, with similar patterns
in each region (Fig. 2) and for both serum creatinine and
UACR tests (data not shown).
The prevalence of measured moderate to severe CKD
(eGFR < 60 ml/min/1.73 m2) increased markedly with
age (Fig. 3). Overall the prevalence (up to 2.3 %) was
1.5–2 times higher in health districts outside Darwin
Urban (Table 2).
In general, the prevalence of measured microalbu-
minuria and overt albuminuria (Fig. 4) increased with
age after 2004; the considerable volatility in older age
groups was consistent with relatively small absolute
numbers. Overall the prevalence of those with a
UACR ≥ 2.5/3.5 (up to 8.1 %) or a UACR ≥ 30 (up to
3.0 %) was four to six times higher in districts out-
side Darwin Urban (Table 2).
Over the whole study period, 39,850 people had ≥2
serum creatinine levels separated by at least 2 years; me-
dian follow-up was 6.8 years with a maximum of
9.9 years. Of these, 1159 people (2.9 % of those assessed)
met the definition for progressive CKD. Table 3 outlines
the risk of progression according to initial CKD stage,
and shows the importance of the initial degree of albu-
minuria and (to a lesser extent) level of eGFR to the risk
of progression.
Discussion
This study describes the overall prevalence of measured
CKD in a region with very high incidence of treated
ESKD and a single dominant (albeit not exclusive) path-
ology service provider. Previous cross-sectional studies
in the region (Additional file 1: Table S1) have described
a very high prevalence of markers of kidney disease in
individual remote communities largely populated by In-
digenous Australians [3–5] and a somewhat lower preva-
lence amongst Indigenous people of the Darwin Urban
region [8]. This study, using existing clinical pathology
data rather than community-wide screening or a
population-based random or weighted sample, has dem-
onstrated a still lower prevalence of CKD, although this
is likely to represent a minimum figure that is still
higher than national estimates.
This lower prevalence could be explained partly by the
“whole of population” approach, which includes a large
number of non-Indigenous people at lower risk of kid-
ney disease. The CKD-EPI formula used in this study
will more correctly estimate a lower proportion with
moderate to severe CKD than the MDRD formula used
in previous studies [9, 20]. In addition, the relatively high
proportion missing UACR tests underestimates the tabu-
lated prevalence of those with CKD and higher (that is,
normal or “near-normal”) eGFRs. These individuals
Table 1 Baseline characteristics by year
Year Individuals tested with
eGFR
Individuals tested with
UACR
Mean
Age
Male
(%)
Darwin Urban
(%)
Darwin Rural
(%)
East Arnhem
(%)
Katherine
(%)
2002 10,046 1141 47.3 48.3 66.9 7.2 10.4 15.5
2003 18,223 1968 46.7 48.0 65.1 9.7 9.7 15.5
2004 20,126 2813 46.5 49.4 63.6 10.2 10.4 15.8
2005 21,764 3562 46.1 47.7 64.1 10.6 10.5 14.7
2006 23,495 3128 46.8 47.6 64.2 10.4 10.6 14.8
2007 27,347 3231 46.4 47.7 63.1 10.3 10.7 15.9
2008 29,709 3942 46.0 48.2 63.6 10.5 10.7 15.2
2009 31,788 3881 46.2 47.2 64.3 10.3 11.0 14.5
2010 30,507 3535 46.4 47.1 62.8 10.6 10.8 15.8
2011 30,246 3616 45.6 47.0 60.3 11.8 11.1 16.8
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appear to behave more like those with normal or “near-
normal” UACRs when progression is examined.
This is the first study to demonstrate the rate of CKD
progression in the region, which appears to be much
higher than that demonstrated in “high-risk population”
studies elsewhere [21]. The degree of proteinuria is a po-
tent predictor of CKD progression, as widely described
elsewhere [21, 22].
There was an initial and substantial rise in the num-
bers tested and in the measured prevalence of CKD
markers from 2002 to 2004. This is well beyond that ex-
pected from an initial incomplete year (2002 results only
are from 1st February due to the commencement of
IDMS standardisation). Although there were changes in
reimbursement for health checks for Indigenous adults
(introduced in 1999 for those over 55, and 2004 for
those aged 15–55 years), these changes are unlikely to
be the main reason for the increase because of the low
uptake of these services [23]. Rather, it is probably best
explained by increased testing as a result of the imple-
mentation of changes in non-communicable chronic dis-
ease care in the Top End in 2002, including increased
funding and resources from changes to pharmaceutical
funding (fully reimbursing costs of medications used in
remote communities) [24] and the commencement and
expansion of remote primary-care based chronic disease
quality improvement research [25].
There was a subsequent steady fall in the prevalence
of measured moderate to severe CKD (eGFR < 60 ml/
min/1.73 m2) as the population size grew and the pro-
portion of the population tested slowly increased, despite
the prevalence of albuminuria increasing. This suggests
that those with more severe kidney disease were identi-
fied by health services early in the time period studied.
It also suggests that either there are many with earlier
stage CKD (particularly with albuminuria alone) who are
still to be identified, or alternatively that in aggregate
across the region the prevalence of markers of earlier
stage CKD is lower than the individual community data
previously published.
There were large differences between the age-specific
prevalence rates in this study and those reported in the
recently released Australian National Health Measures
Survey (NHMS), although such comparisons must be
made with extreme caution as remote areas were ex-
cluded from the NHMS and the proportion of Indigen-
ous respondents was very small [26]. Whilst the
prevalence of moderate to severe CKD (eGFR < 60 ml/
min/1.73 m2) in those over 65 years was similar in this
study and in the NHMS, rates for those between 35 and
65 years in the Top End of the NT were double national
rates. In contrast rates of albuminuria in the Top End
were significantly lower than national rates at every age
group. This also suggests either that there are many
more people with albuminuria yet to be identified in the
Top End of the NT or that they were tested using point-
of-care technology rather than laboratory testing [27].
Also relevant are comparisons with data from the re-
cently released National Aboriginal and Torres Strait
Islander Health Measures Survey (NATSIHMS), which
aimed to be a representative sample of Indigenous
Australians from 2012–13 [28]. The prevalence of those
with eGFR < 60 ml/min/1.73 m2 in non-urban health
districts was slightly lower in these Top End data than in
Darwin Rural
Katherine
East Arnhem
Darwin Urban
0
10
20
30
40
50
2002 2003 2004 2005 2006 2007 2008 2009 2010 2011
Year
Proportion of population tested by WDP by district, per year
Fig. 2 Proportion of adult population tested by Western Diagnostic Pathology by health district, per year
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the NATSIHMS; again, rates of albuminuria in these
Top End data were significantly lower than national In-
digenous rates. Unfortunately, NATSIHMS rates by age
groups have not been released for comparison.
To our knowledge, this is the first study to use meth-
odology that includes cases known to be alive, despite
not being tested, in interval years to calculate preva-
lence. This “carrying forward” approach may underesti-
mate fluctuations in kidney function and albuminuria
over time. This approach also assumes that the Top
End’s population does not leave and then return to
the Top End after long periods of time. Whilst an es-
timate of those returning to the NT is not available,
2001 ABS census data estimated that 89.4 % of
Indigenous Top End residents and 67.0 % of non-
Indigenous Top End residents lived in the same
Health District 5 years before [29].
In the vast majority of individuals, calculation of mean
eGFR and mean UACR relied upon one test only, and this
might result in an overestimate in prevalence of CKD
markers, particularly low-level albuminuria [30, 31]. The
collection of these data predated revisions to the definition
of CKD that now incorporate both eGFR and UACR sim-
ultaneously; during the time of this study testing was se-
quential (based on local guidelines) and eGFR-UACR
“paired” samples uncommon.
Data about the proportion of tests processed by indi-
vidual pathology providers in Australia are closely held
by government and thought “commercially sensitive”; as
a result, it is not possible to document the extent of
Western Diagnostic Pathology’s dominance in the region
over the time of study. Replicating this work for the
whole of the NT or for other Australia states would re-
quire linking records from more than one pathology
Table 2 Prevalence (%) of Markers of CKD by District, 2009a
District Number
UACR tests
Percent ERPb tested
with UACR
Percent with Mean
UACR≥ 2.5/3.5
Percent with Mean
UACR≥ 30
Number eGFR
tests
Percent ERPb tested
with eGFR
Percent with Mean
eGFR < 60
Darwin Urban 7070 7.2 1.6 0.5 28,790 29.2 1.1
Darwin Rural 2295 19.5 8.1 2.8 4147 35.2 1.8
East Arnhem 2223 18.5 6.9 2.4 4458 37.1 1.5
Katherine 2974 20.9 8.1 3.0 6132 43.2 2.3
a Represents 2009 results as well as results prior to 2009 carried forward if there were no 2009 results but both pre-2009 and post-2009 data were available
(see Methods)
b Estimated Resident Population 15 years and over
.1
.2
.3
.4
.5
1
2
3
4
5
10
20
30
2002 2003 2004 2005 2006 2007 2008 2009 2010 2011
Year
75+
65-74
55-64
45-54
35-44
25-34
15-24
Prevalence of eGFR<60 in Top End NT, by age groups, both genders
Fig. 3 Prevalence of eGFR < 60 ml/min/1.73 m2 in Top End NT, by age groups, both genders
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provider. Because Indigenous status is not recorded in
pathology data, calculating separate Indigenous and
non-Indigenous estimates of CKD prevalence would re-
quire linkage with other datasets that include an Indi-
genous identifier (such as hospitalisation data). Linkage
would also reduce the chances of multiple identifiers
leading to an overestimate of prevalence, particularly for
Indigenous Territorians.
The absence of dataset linkage also means that this
study is unable to determine accurately the total number
of ESKD cases not receiving treatment, as it is possible
that some of those receiving RRT had some blood tests
through Western Diagnostic Pathology even though the
dominant pathology provider for these individuals would
have been the public hospital based pathology service.
This study used existing clinical pathology data rather
than a population-based random sample or community-
wide screening as attempted in other studies
summarised in the Additional file 1: Table S1. As a re-
sult, inferences drawn about those not tested, and the
population as a whole, are limited. Different approaches
to testing for CKD in urban and remote areas of the Top
End of the NT are likely to limit the validity of compari-
sons between them, given specific guidelines [32] and
awareness of the heightened ESKD risk for Indigenous
people in remote areas of the NT. The prevalence
Table 3 Percentagea with progressive CKDb, whole time period
Initial eGFR group Initial UACR <3.4 Initial UACR 3.4–9.9 Initial UACR 10–29 Initial UACR 30–299 Initial UACR >300 Missing UACR
105+ 0.3 1.9 1.7 7.9 53.1 0.2
90–104 0.6 2.5 3.7 13.9 66.6 0.3
75–89 1.7 3.0 4.3 23.0 61.7 1.3
60–74 3.6 15.4 22.5 40.1 71.8 5.7
45–59 6.4 10.6 20.9 42.2 95.6 13.4
30–44 4.9 7.8 25.6 57.6 84.3 26.1
15–29 0.0 11.0 19.2 56.2 55.0 34.9
0–14 0.0 0.0 0.0 13.8 100.0 9.9
a Percentage is of those with 2 or more creatinine measurements at least 2 years apart (N = 39,850)
b Progressive CKD defined as average annual decline of >2.5 ml/min/1.73 m2/year, with final eGFR <45 ml/min/1.73 m2, minimum follow-up 2 years [11]
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65-74
55-64
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35-44
25-34
15-24
Includes urine ACR >2.4 for men & >3.4 for women
Prevalence of Albuminuria in Top End NT, by age groups, both genders
Fig. 4 Prevalence of Albuminuria in Top End NT, by age groups, both genders
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figures shown, however, do provide minimum estimates
for the whole population; they are useful in the absence
of a population based random sample of the region
which is unlikely in the foreseeable future due to the
competing demands and prohibitive expense of research
in such a remote, culturally diverse environment.
The prevalence of measured CKD, even if the whole
population were tested, is only one measure of the bur-
den of disease. Because prevalence is related to both in-
cidence and duration, substantial differences in the
incidence of and survival from disease may be masked
within similar prevalence figures between populations.
Conclusions
This study provides useful information for planning and
policy development. Both the rate of testing and the
minimum estimates of the prevalence of markers of
CKD are much higher in non-urban health districts of
the Top End, but still lower than previous community-
based surveys. Rates of moderate to severe CKD in mid-
dle age in the Top End are double national figures. As
testing rates have increased over the last decade, the
prevalence of measured albuminuria has increased but
moderate to severe CKD has not. The rate of CKD pro-
gression is much higher than that published for other
high-risk populations. To determine better the incidence
and outcomes of CKD across this or other regions, in-
cluding its association with Indigenous status, studies
using linked data from multiple sources will be required.
Now that data linkage systems are developing in
Australia, it should be possible to do this in the near
future.
Additional file
Additional file 1: Table S1. Comparison of overall prevalence of
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